Ribociclib: as the comparator
10 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNCT07706933Not applicableReport a problem
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruitingNCT07492641Phase 3Report a problem
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingNCT06757634Phase 3Report a problem
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingNCT06486883Phase 2Report a problem
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingNCT05900206Phase 2Report a problem
- A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCRecruitingNCT05766410Phase 2Report a problem
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingNCT06760637Phase 3Report a problem
- A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast CancerWithdrawnNCT06585969Phase 3Report a problem
- Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibTerminatedNCT05625087Phase 2Report a problem
- CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDOCompletedNCT03227328Phase 2Report a problem